Our BD SurePath™ brand defines a liquid-based Pap test that improves disease detection.

SurePath AI is a SaaS platform that governs any GenAI solutions you build, adopt, or buy—even Shadow AI.

SurePath™ Pap - Liquid based Pap testing is intended for use in the screening and detection of cervical cancer, pre-cancerous lesions, atypical cells and all other cytologic categories as defined by the …

The BD SurePath Collection Vial offers standardization and positive sample identification, while providing physicians with a single-source collection for Pap screening and molecular diagnostic testing.

The BD SurePath™ liquid-based Pap test provides advantages over conventional Pap smears and other liquid-based cytology (LBC) tests, resulting in greater disease detection.

Our comprehensive platform governs end-user GenAI use, allowing businesses to harness public GenAI services, access private models, and control data flow—all while ensuring security and compliance.

Transform shadow AI into an advantage. Secure GenAI adoption with both public and private model management and visibility. Future-proof your enterprise AI strategy with SurePath.

The BD SurePath™ liquid-based Pap test provides advantages over conventional Pap smears and other liquid-based cytology (LBC) tests, resulting in greater disease detection.

The BD SurePath™ collection vial is designed to improve patient care while providing physicians with the convenience of a single-source collection for Pap screening and molecular diagnostic testing

Feb 10, 2025 · We’re excited to introduce SurePath AI Assistants, a powerful new way to streamline workflows and enhance productivity across your organization.